Stocktoria
MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2020-11-20
MARAVAI LIFESCIENCES HOLDINGS, INC. financials (annual)
Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $185.7M | $259.2M | $288.9M | $883.0M | $799.2M | $284.1M |
| Gross profit | $34.0M | $108.3M | $140.2M | — | — | — |
| R&D expense | $17.4M | $19.2M | $17.3M | $18.4M | $15.2M | $9.3M |
| SG&A expense | $145.1M | $161.8M | $151.4M | $129.3M | $100.1M | $94.2M |
| Operating income | -$215.3M | -$235.6M | -$31.6M | $574.2M | $554.6M | $119.9M |
| Interest expense | — | — | $45.9M | $20.4M | $30.3M | $30.7M |
| Income tax | -$4.2M | -$1.9M | $756.1M | $60.8M | $61.5M | $2.9M |
| Net income | -$130.8M | -$144.8M | -$119.0M | $220.2M | $182.0M | $89.0M |
| EPS (diluted) | $-0.90 | $-1.05 | $-0.90 | $1.67 | $1.56 | $2.36 |
| Operating cash flow | -$57.6M | $7.5M | $126.2M | $536.0M | $368.6M | $152.2M |
| Free cash flow | -$70.7M | -$22.2M | $60.7M | $518.9M | $353.7M | $126.8M |
| Cash & equivalents | $216.9M | $322.4M | $575.0M | $632.1M | — | — |
| Inventory | $40.5M | $50.1M | $51.4M | $43.2M | $51.6M | $33.3M |
| Total assets | $770.6M | $1.0B | $1.5B | $2.3B | $1.9B | $1.3B |
| Total liabilities | $397.9M | $431.0M | $697.6M | $1.4B | $1.4B | $1.1B |
| Shareholders' equity | $372.7M | $577.2M | $789.9M | $905.2M | $545.4M | $154.7M |
Growth · year-over-year · Revenue CAGR -8.1%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue growth | -28.3% | -10.3% | -67.3% | +10.5% | +181.3% | — |
| Net income growth | — | — | -154.1% | +21.0% | +104.6% | — |
| EPS growth | — | — | -153.9% | +7.1% | -33.9% | — |
| Free cash flow growth | — | -136.6% | -88.3% | +46.7% | +179.0% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.